索拉非尼联合化疗栓塞治疗晚期原发性肝癌的疗效分析  

Clinical Effects of Sorafenib Combined with Transcatheter Arterial Chemoembolization on the Treatment of Advanced Primary Hepatocellular Carcinoma

作　　者：周仁贵[1] 周锡建[1] 李相勇[1] 夏云宝[2] 宋鹏[1] 郭晓东[3] 

机构地区：[1]解放军第101医院血液肿瘤科,江苏无锡214044 [2]解放军第101医院影像科,江苏无锡214044 [3]解放军第302医院,北京100039

出　　处：《现代生物医学进展》2014年第13期2494-2496,共3页Progress in Modern Biomedicine

基　　金：国家自然科学基金青年科学基金项目(30901795)

摘　　要：目的:原发性肝癌(Primary hepatocellular carcinoma,PHC)是最常见的消化系统恶性肿瘤之一,严重威胁人类的健康。目前,治疗晚期肝癌的首选方法是肝动脉化疗栓塞(Transcatheter arterial chemoembolization,TACE),配合抗癌药物使用,治疗效果明显。索拉非尼因具有抑制肿瘤生长的作用而被越来越广泛的用于治疗肝癌。本研究针对索拉非尼的靶向性,探讨该药与化疗栓塞联合治疗晚期原发性肝癌的疗效,旨在为肝癌的临床治疗提供可参考的依据。方法:选取我院2008年10月-2012年6月收治的晚期原发性肝癌患者96例,随机分为对照组和观察组,每组各48例。对照组患者采用肝动脉化疗栓塞单独治疗,观察组患者采用索拉非尼联合化疗栓塞治疗。比较两组患者的客观有效率、临床获益率、治疗一年生存率、两年以上生存率及甲胎蛋白(AFP)水平的变化情况。结果:观察组患者的客观有效率为52.1%,临床获益率为89.6%,均高于对照组患者的对应值33.3%和47.9%,差异有统计学意义(P<0.05);观察组患者一年生存率为89.6%,两年生存率为72.9%,均高于对照组患者的对应值58.3%和35.4%,差异显著(P<0.05);两组患者治疗后的AFP水平均比治疗前降低,观察组患者AFP水平的改善情况显著优于对照组,差异具有统计学意义(P<0.05)。结论:索拉非尼联合化疗栓塞治疗晚期原发性肝癌具有明显的效果,且安全性高,值得临床推广使用。Objective： Primary hepatocellular carcinoma（PHC） is one of the most common malignant tumors in the digestion system which is a serious threat to human health. At present, the preferred method of the advanced PHC is the transcatheter arterial chemoembolization（TACE） that could be better when combined with the anti-cancer drugs. With the function of inhibiting tumor cells＇ growth, sorafenib has been widely applied on the treatment of liver cancer. In view of the targeted qualification of the sorafenib, this study is written to discuss the curative effects of sorafenib combined with TACE on the treatment of advanced primary liver cancer, so that we could provide some references for clinical research. Methods： 96 cases with the advanced hepatocellular carcinoma who were treated in our hospital from October 2008 to June 2012 were selected and randomly divided into the control group and the observation group with 48 patients in each group. The patients in the control group were treated only by the TACE, while the patients in the observation group were treated by the sorafenib combined with TACE. Then the objective response rate（ORR）, the clinical benefit rate（CBR）, the survival rate of one year, the survival rate of more than two years and the alphafetoprotein（AFP） changes of patients were compared between two groups. Results： The ORR of the patients in the observation group was 52.1% and the CBR was 89.6% which were higher than those of the patients in the control group（33.3% and 47.9%） with statistical significant differences（P〈0.05）. The survival rate of one year and more than two years were 89.6% and 72.9% which were higher than those of the patients in the control group（58.3% and 35.4%） with statistical significant differences（P〈0.05）. The AFP levels were decreased of patients both in the two groups, but in which the observation group was superior to the control group（P〈0.05）. Conclusion： It＇s worthy to widely promote the application of sorafenib combined w

关 键 词：索拉菲尼 TACE 原发性肝癌 临床效果 

分 类 号：R735.7[医药卫生—肿瘤]